Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for Candesartan Cilexetil

    Client Email Product

    Candesartan Cilexetil

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    60
    US DMFs Filed

    US DMFs Filed

    22
    CEP/COS Certifications

    CEP/COS Certifications

    23
    JDMFs Filed

    JDMFs Filed

    15
    Other Certificates

    Other Certificates

    15
    Other Suppliers

    Other Suppliers

    20
    API REF. PRICE (USD / KG)
    751

    API Market Place

    10
    INTERMEDIATES
    20
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    51
    Europe

    Europe

    542
    Canada

    Canada

    78
    Australia

    Australia

    3
    South Africa

    South Africa

    21
    Uploaded Dossiers

    Uploaded Dossiers

    45
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    365.00

    Annual Reports

    0

    FDF Market Place

    2
    EXCIPIENTS
    111
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    2

    News

    30
    REF STANDARD

    EDQM

    3

    USP

    6

    JP

    0

    Other Listed Suppliers

    7
    SERVICES

    0

    left grey arrow
    right gray arrow
    • TABLET;ORAL - 16MG
    • TABLET;ORAL - 32MG
    • TABLET;ORAL - 4MG
    • TABLET;ORAL - 8MG
    • TABLET;ORAL - 16MG;12.5MG
    • TABLET;ORAL - 32MG;12.5MG
    • TABLET;ORAL - 32MG;25MG
    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights

    Details:

    The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).


    Lead Product(s): Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Midas Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership December 14, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed

    Details:

    AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).


    Lead Product(s): Candesartan Cilexetil

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

    Deal Size: $400.0 million Upfront Cash: Undisclosed

    Deal Type: Divestment January 04, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries

    Details:

    AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.


    Lead Product(s): Candesartan Cilexetil

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

    Deal Size: $400.0 million Upfront Cash: Undisclosed

    Deal Type: Divestment October 30, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search